Gå direkt till huvudinnehållet

Vaskuliter, systemiska

Senast reviderad:
Sakkunnig:


  1. Sharma P, Sharma S, Baltaro R, Hurley J. Systemic vasculitis. Am Fam Physician 2011; 83: 556-65. PMID: 21391523 PubMed  
  2. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005; 53: 93-9. PubMed  
  3. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92. PubMed  
  4. Sørensen SF, Slot O, Tvede N, Petersen J. A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis 2000; 59: 478-82. PubMed  
  5. Basu N, Watts R, Bajema I, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 2010; 69: 1744-50. PubMed  
  6. Serra R, Butrico L, Fugetto F, et al. Updates in Pathophysiology, Diagnosis and Management of Takayasu Arteritis. Ann Vasc Surg. 2016 Aug;35:210-25. Epub 2016 May 27.PMID: 27238990 PubMed  
  7. Sneller MC, Fauci AS. Pathogenesis of vasculitis syndromes. Med Clin North Am 1997; 81: 221-42. PubMed  
  8. Danila MI, Bridges SL Jr. Update on pathogenic mechanisms of systemic necrotizing vasculitis. Curr Rheumatol Rep 2008; 10: 430-35. PubMed  
  9. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222-7. PubMed  
  10. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis & Rheumatism 1990;33:1088-134. [url]http://onlinelibrary.wiley.com/doi/10.1002/art.v33:8/issuetoc[/url] PMID: 2390119 PubMed  
  11. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of anti-neutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126: 866-73. PMID: 9163287 PubMed  
  12. Roggenbuck D, Buettner T, Hoffmann L, Schmechta H, Reinhold D, Conrad K. High-sensitivity detection of autoantibodies against proteinase-3 by a novel third-generation enzyme-linked immunosorbent assay. Ann N Y Acad Sci 2009; 1173: 41-6. PubMed  
  13. Savige J, Pollock W, Trevisin M. What do antineutrophil cytoplasmic antibodies (ANCA) tell us? Best Pract Res Clin Rheumatol 2005; 19: 263-76. PubMed  
  14. Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143: 621-31. PMID: 16263884 PubMed  
  15. Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. �Arthritis Rheum 2008; 58: 2908-18. PMID: 18759282 PubMed  
  16. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337: 1512-23. PMID: 9366584 PubMed  
  17. Baer AZ, Rubin LG, Shapiro CA, et al. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome. Arch Pediatr Adolesc Med 2006; 160: 686-90. PubMed  
  18. Espinola-Zavaleta N, Soto ME, Bauk L, et al. Coronary reserve in Takayasu's arteritis: transesophageal echocardiographic analysis. Echocardiography 2005; 22: 593-8. PubMed  
  19. Bourgarit A, Le Toumelin P, Pagnoux C, Cohen P, Mahr A, Le Guern V, Mouthon L, Guillevin L. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84: 323-30. PubMed  
  20. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003; 30: 80-8. PubMed  
  21. Nataraja A, Mukhtyar C, Hellmich B, Langford C, Luqmani R. Outpatient assessment of systemic vasculitis. Best Pract Res Clin Rheumatol 2007; 21: 713-32. PubMed  
  22. Osman M, Pagnoux C, Dryden DM, et al. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. PLoS One. 2014 Dec 17;9(12):e115026. PubMed  
  23. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; Jul 15;363(3): 221-32. pmid:20647199 PubMed  
  24. Heijl C, Harper L, Flossmann O, Stücker I, Scott DG, Watts RA, Höglund P, Westman K, Mahr A. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011; 70: 1415-21. PubMed  
  25. Pagnoux C, Chironi G, Simon A, Guillevin L. Atherosclerosis in ANCA-associated vasculitides. Ann N Y Acad Sci 2007; 1107: 11-21. PubMed  
  • Tomas Zweig, överläkare, Reumatologkliniken, Karolinska Universitetssjukhuset, Solna
  • Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet